Dorine, Hi! It looks like things are picking up again for the Dell longs! :)Leigh
Last year Dell's earnings slowed in the fourth quarter because Y2K concerns curbed corporate clients' tech spending and investors feared that smart wireless devices would undercut desktop computer sales. Loewenstein and his colleagues believe the company is headed for a solid earnings recovery that will send the stock north.
"Right now, it's a company selling at its growth rate. We think the stock is headed up 50%," he says.
thestreet.com
Saturday Screen: Overlooked Earnings Stories By Ian McDonald Senior Writer 3/4/00 10:50 AM ET
Today's market is being driven by a narrow band of biotech, wireless and tech stocks, and that's leaving plenty of solid companies in the growth highway's breakdown lane.
So, this week's Saturday Screen trolls the S&P 500 for the best of these overlooked growth stocks.
We sifted the S&P 500 for large-cap stocks that have been growing earnings at a 20% annual clip and are expected to do so over the next five years, but have underperformed the S&P 500 index over the past 12 months. After all, stock prices are supposed to follow earnings, right?
We came up with a list of 15.
But What Have You Done for Me Lately? Stocks with golden earnings outlooks that have gone nowhere. Stock Trailing 12-Month Earnings Growth Projected 5-Yr. Earnings Growth 12-Month Performance P/E Ratio MCI WorldCom (WCOM:Nasdaq - news - boards) 191% 29% -14.8% 34.7 Providian Financial (PVN:NYSE - news - boards) 85 25 -35.5 17.2 Boston Scientific (BSX:NYSE - news - boards) 56 20 -35.4 17.5 Tyco International (TYC:nyse - news - boards) 53 20 5.6 22.9 Compuware (CPWR:Nasdaq - news - boards) 52 30 -23.9 18.2 Unisys (UIS:NYSE - news - boards) 44 20 0.4 19.3 Gap (GPS:NYSE - news - boards) 39 20 10.9 37.8 Pfizer (PFE:NYSE - news - boards) 36 20 -28 36.9 Staples (SPLS:NYSE - news - boards) 35 30 -10.2 41.1 Lowe's Companies (LOW:NYSE - news - boards) 34 21 -19.4 26.6 Capital One Financial (COF:NYSE - news - boards)COF 30 23 -12.2 21.9 Dell Computer (DELL:Nasdaq - news - boards) 29 32 6.8 62.3 Cardinal Health (CAH:NYSE - news - boards) 26 20 -45.2 17 MBNA (KRB:NYSE - news - boards)KRB 25 20 -5.1 19.2 Dollar General (DG:NYSE - news - boards) 21 23 -16.6 24.9 S&P 500 9 9 13 28.4 Source: Baseline. Data through March 2.
We don't claim this is a buy list by any stretch of the imagination, but you might find a few intriguing ideas in this pack. Guest columnist Jim Jubak recently listed two stocks from the list, Dell Computer (DELL:Nasdaq - news - boards) and Pfizer (PFE:NYSE - news - boards) in his column on the 10 best stocks to own now.
These stocks' earnings growth looks good on paper, but their performance tells you that some may have had problems. (Hello, Tyco (TYC:NYSE - news - boards)!)
But today's moody market has sometimes been too kind to unprofitable concept stocks and too cruel to solid companies recovering from an earnings hiccup. We showed this list to some money managers and asked them to look behind the numbers and help us separate the wheat from the chaff.
MCI WorldCom (WCOM:Nasdaq - news - boards) and Dell both stumbled last year, but could be set to recover this year, says Alan Loewenstein, co-manager of John Hancock Global Technology, up 178% over the past year. He owns both stocks in the fund.
Price competition on long-distance rates and acquisition growing pains weighed down MCI WorldCom shares. But Loewenstein says the company's growing revenue from data communications will boost the stock this year.
Last year Dell's earnings slowed in the fourth quarter because Y2K concerns curbed corporate clients' tech spending and investors feared that smart wireless devices would undercut desktop computer sales. Loewenstein and his colleagues believe the company is headed for a solid earnings recovery that will send the stock north.
"Right now, it's a company selling at its growth rate. We think the stock is headed up 50%," he says.
Investors haven't been quite so optimistic about nonbiotech health care stocks lately. Expiring drug patents and fears that legislators will cap drug and health care costs have pushed this one-time growth sector onto many value managers' radar screens.
But there's good reason to take a closer look at pharmaceutical giant Pfizer and drug-distributor Cardinal Health (CAH:NYSE - news - boards), says Jordan Schreiber, skipper of Merrill Lynch Healthcare, whose 29% average annual return beats 85% of his peers, according to Morningstar. He owns both stocks in his fund.
Pfizer is more than 30% below its 52-week high and is in the midst of swallowing Warner-Lambert (WLA:NYSE - news - boards). The American Stock Exchange Pharmaceutical index is down more than 9% since Jan. 1, but to say Schreiber likes the stock is an understatement.
"Pfizer will be the most dominant drug company in the world when they integrate Warner-Lambert. They'll have the biggest product pipe and the best marketing in the industry," he says.
Cardinal Health suffers from the sector's woes, too, in addition to making some dicey acquisitions. The company, nearly 50% off its 52-week high, also was tarred with the same brush as troubled competitor McKesson HBOC (MCK:NYSE - news - boards). But Schreiber believes in the company's management and thinks its new Internet strategy will help silence critics and send the stock up.
Things aren't as rosy among the retailers, where managers say the threat of Internet competitors and a slowing economy have hurt the whole sector, including the likes of Gap (GPS:NYSE - news - boards) and Staples (SPLS:Nasdaq - news - boards).
But Lowe's Companies (LOW:NYSE - news - boards) might be worth a look, says Bruce White, a private money manager with Clifford Associates in Pasadena, Calif.
"It's a hell of bargain," says the usually low-key White, who owns the stock personally and on behalf of clients.
The company is essentially a "Home Depot (HD:NYSE - news - boards) look-alike," says White. Traditionally, Lowe's has refrained from competing with Home Depot in metropolitan areas, but now it's taking the challenge, he says. Wall Street doesn't think the company can do it and has punished the stock in the face of solid earnings.
Wall Street has written off Lowe's simply because analysts love Home Depot, but Lowe's management is savvy enough to make the expansion a success, says White. He thinks once the company proves itself a solid competitor in metro areas, the stock, which is nearly 30% below its 52-week high, will be rewarded.
Dollar General (DG:NYSE - news - boards) is a discount retailer that might be a good play as the Wal Mart (WMT:NYSE - news - boards) "for the low-income person," if the company can cut costs and boost margins, says Dean DuMonthier, who manages Strong Mid-Cap Discipline, up 43% over the past year.
"The low stock price can compensate you for the risk you're taking," he says. The stock is nearly 40% below its 52-week high and its price-to-earnings ratio is well below its peers.
He also likes Capital One (COF:NYSE - news - boards), which he owns in his fund, one of the three credit card shops on our list. As you may imagine, the group on the whole has been under pressure. Even though personal bankruptcies are at an all-time low, investors figure an economic slowdown could create a real credit crunch for these companies, particularly Capital One and Providian Financial (PVN:NYSE - news - boards), both of which have exposure to consumers with less-than-perfect credit.
An earnings slowdown at Bank One (ONE:NYSE - news - boards) last year and regulators' probe into Providian's sales practices have hurt the group, too. But DuMonthier says Capital One's solid management should be able to sidestep its competitors' problems, and he doesn't see a steep downturn ahead. That, he says, makes the cheap stock a bargain.
Is he right? Only time will tell. And the same goes for the others on our list. No one can say for sure which of these stocks will turn around. But it's hard to ignore 20% annual earnings growth forever. |